WIN is Very Proud to Announce That Institut Curie, France Has Joined Its Consortium

Posted: Wednesday, June 01, 2016

VILLEJUIF, France--(BUSINESS WIRE)--“We are very proud to welcome Institut Curie to WIN,” said Dr. John Mendelsohn, Chairman of WIN and Director of the Khalifa Institute for Personalized Cancer Therapy and past President of MD Anderson Cancer Center.“The Institut Curie is undeniably a leading European cancer research center with remarkable research that will constitute a major asset for WIN.”

WIN’s mission is to rapidly translate precision cancer medicine discoveries into standards of patient care worldwide. “Our vision and value proposition is that we can accomplish more together than each organization can achieve working alone. In WIN, renown academics and industries work hand in hand to develop the tools and therapies needed to significantly improve survival and quality of life of cancer patients from diverse backgrounds.” said Dr. Vladimir Lazar, Chief Operating Officer of WIN. WIN, through its network of academics, industries, insurance and patient advocates, is present in 14 countries and 4 continents. Not only it provides an effective platform to launch clinical trials but it is the place where transformational proof of concept trials paving the way for the future of cancer care can be developed, such as WINTHER, first trial of the WIN Consortium which was selected as a Success Story of the EUFP7.

WIN enables simultaneous access to patients with varied genetic backgrounds, enhancing the speed and efficacy with which novel discoveries can be made, in particular new biomarkers, and brought to patients around the world. Industry members contribute by developing the tools, to select the best therapies to treat patients: biological investigations of genes and gene products and algorithms.

“Precision cancer medicine remains very challenging, as the results of our SHIVA study prove. “ said Prof. Thierry Philip, President of Institut Curie. “We are thrilled to be able to present SHIVA and debate about the conclusions we can draw from the study at the WIN annual symposium on June 28-27 in Paris.”

"What SHIVA tells us is that we need to continue doing research in this area of personalized medicine,” said Dr. Richard L.Schilsky Chief Medical Officer of ASCO and chairman of WIN SAB.

Vladimir Lazar, +33-66-109-15-22
Institut Curie

WIN represents a global collaboration of cancer centers, life science and biotech organizations, pharmaceutical and technology companies and not-for-profit organizations.
The Worldwide Innovative Networking (WIN) Consortium in personalized cancer medicine was initiated in 2010 with leadership from leading cancer centers worldwide. WIN is a non-profit, non-governmental organization headquartered in Paris.

WIN was created to accelerate the pace and reduce the cost of translating novel cancer treatments to the bedside by developing and applying, through worldwide clinical trials and research projects, the most promising advances in genomic-based cancer research. WIN aims to initiate research projects each year in a global consortium guided by an independent scientific advisory board.

WIN now includes 37 institutional members. These stakeholders have come together from all parts of the world to address the challenge of increasing the efficacy of cancer diagnostics and therapeutics by understanding the genetics and biology of each individual’s tumor and accounting for genetic differences across diverse populations—from North and South America, Europe, Asia, and the Middle East.

Our goal is to significantly improve outcomes for patients around the globe. We aim to increase the number of patients worldwide that have access to innovative, global clinical trials in the area of genomic-based cancer therapeutics. Global diversity and inclusion of all stakeholders is WIN’s most important and differentiating asset.
WIN is comprised of organizations representing all stakeholders in personalized cancer medicine.
WIN enables cross-sector collaborations designed to accelerate the speed and efficacy with which breakthroughs in personalized cancer medicine can be realized and brought to patients worldwide.

Our members include leading academic, pharmaceutical, life science, not-for-profit, health, patient advocacy and IT organizations.
Our members include 28 leading academic centers representing 20 countries and four continents, enabling coordinated studies with a global patient population.
The response to a genetically-targeted therapy can vary due to differences in ethnicity and environment. WIN's global studies are designed to identify and account for this variability, enhancing the speed and efficacy with which novel discoveries can be made and brought to patients around the world.

WIN prioritizes cross-sector interaction designed to enhance learning across and between continents and healthcare sectors.
WIN Symposia, held annually, brings together hundreds of leaders representing all stakeholders from around the world in a forum designed to promote the exchange of ideas and information.